CliffBio
small molecule

BEYAZ

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

Loss of exclusivityJuly 2030latest FDA-listed patent expiry
CompanyBayer Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameBEYAZ
Active ingredientDROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM
Strength3MG,N/A;0.02MG,N/A;0.451MG,0.451MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2010
Marketing statusRX

Listed patents

PatentExpiresType
11617751July 2030product
8617597February 2030product

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BEYAZ patent cliff — loss of exclusivity July 2030 | CliffBio